KNSA Stock — Kiniksa Pharmaceuticals International plc Class A: Cash, EV, Pipeline

Share price

$77.24

Market cap

$6,026.6M

Cash

$175.7M

Enterprise value

$5,850.9M

Balance sheet

Cash	$175.7M
Debt	$0.0M
Net cash	$175.7M
Enterprise value	$5,850.9M
Basic shares	83.4M shares
Fully diluted shares	95.6M shares
Fully diluted market cap	$7,383.7M
Cash per share	$2.11

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading KNSA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 24	KPL-387	Phase 3	Pericarditis; Pericarditis Acute; Recurrent Pericarditis	—
Feb 11 - Mar 24	KPL-387	Phase 2	Recurrent Pericarditis; Heart Diseases; Pericarditis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ARCALYST (rilonacept)

Approved · Active

Target IL-1α/IL-1β

Partnerships Regeneron: exclusive license (BLA transferred after RHAPSODY Phase 3); Huadong: exclusive rights to develop/commercialize ARCALYST in China/Hong Kong/Macao/Taiwan and SE/South Asia territory (upfront $12M, $20M regulatory milestone owed in 2024, up to ~$50M sales milestones, tiered royalties)

Indications

Recurrent pericarditis (reduction in risk of recurrence, adults and children 12+) (Approved)
Cryopyrin-Associated Periodic Syndromes (Approved)
Deficiency of Interleukin-1 Receptor Antagonist (Approved)

Status note FDA approved March 2021 for recurrent pericarditis and reduction in risk of recurrence (adults and children 12+). Company assumed US sales/distribution for CAPS and DIRA. ARCALYST is a registered trademark of Regeneron.

KPL-387

Stage not disclosed · Active Modality: Monoclonal antibody (fully human IgG2)

Target IL-1R1 (interleukin-1 receptor 1; inhibits IL-1alpha/IL-1beta signaling)

Partnerships n/a (independently developed)

Indications

Recurrent pericarditis (Stage not disclosed)

Status note Filing states the company expects to begin commercializing KPL-387 in 2028 or 2029. Trial-phase and data-timing details appear only in the 10-K fallback section of the source material, not the primary 10-Q.

KPL-1161

Preclinical · Active Modality: Monoclonal antibody (Fc-modified IgG2)

Target IL-1R1 (interleukin-1 receptor 1; inhibits IL-1alpha/IL-1beta signaling)

Partnerships n/a (independently developed)

Indications

not disclosed (Preclinical)

Status note Preclinical, modified version of KPL-387 designed for increased half-life supporting potential quarterly SC dosing. Company plans to initiate a Phase 1 first-in-human trial by end of 2026.

Abiprubart

Phase 2 · Terminated Modality: Monoclonal antibody

Target CD40-CD154 costimulatory interaction

Partnerships Beth Israel Deaconess Medical Center: exclusive worldwide license

Indications

Sjogren's Disease (Phase 2)

Status note Feb 2025: company announced plans to discontinue development of abiprubart in Sjogren's Disease (was a Phase 2b trial) and to explore strategic alternatives for the asset. Clinical supply agreements with CDMOs terminated (Feb 2025).

Per-asset detail extracted from the 10-Q filed 2026-07-28. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	KPL-387
Lead indication	Pericarditis
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07010159	Phase 3	Recruiting	Sponsor	KNSA	—	Pericarditis; Pericarditis Acute; Recurrent Pericarditis	—
NCT07288216	Phase 2	Recruiting	Sponsor	KNSA	—	Recurrent Pericarditis; Heart Diseases; Pericarditis	—
NCT04687358	Not disclosed	Active, not recruiting	Sponsor	KNSA	—	Recurrent Pericarditis	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Kiniksa Pharmaceuticals International, plc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	2,834,643	+8,397	0.91%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

KNSA — Kiniksa Pharmaceuticals International plc Class A

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders